Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
DelSiTech Ltd, a Finnish drug delivery technology and drug development company, and Bayer have signed a collaboration and technology licence agreement for the worldwide application of DelSiTech’s Silica Matrix drug delivery platform to a number of Bayer’s compounds in ophthalmology.
Amgen and Arrowhead Pharmaceuticals Inc. announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. These are the first programs to utilize Arrowhead's proprietary subcutaneous RNAi delivery platform. RNAi molecules may be designed to target and shut down specific gene products that contribute to various diseases.
Zydus Cadila, a research-driven, global healthcare provider and Medicines for Malaria Venture (MMV) announced a collaboration to develop the investigational antimalarial compound, MMV674253. Zydus will lead the development of the novel compound and MMV will provide support including scientific expertise and access to tools in the field of malaria drug development and delivery.
Life saving drug (D-Penicillamine) is not available across India. And CDSCO working faster on availability of drug in the market.
MSD, Verastem, Inc. and Cancer Research UK will trial a new combination of immunotherapy drugs in mesothelioma, non small cell lung and pancreatic cancers. The trial will run through the ECMC network at centres in Edinburgh-Dundee, Southampton, Glasgow, Leicester and Belfast.
[adsense:336x280:8701650588]
Nanobiomed Inc®., a nanomedicine and biotechnology company announced its leading-edge development of a new molecule for use in tissue and cancer diagnostics.
Sun Pharmaceutical Industries Ltd announce latebreaking data from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) achieving the primary endpoint with tildrakizumab, an investigational IL-23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria. As indicated in a previous press release, top line results from these studies were announced on May 4, 2016.
“Infection during pregnancy and during the postpregnancy period is a major health problem for both mom and baby, and a common underlying cause of death,” said Alan T. N. Tita, M.D., Ph.D.; professor in the UAB Division of Maternal-Fetal Medicine and the Center for Women’s Reproductive Health, and principal investigator of the study. “Women who have a C-section are at significantly increased risk for infection compared to those who deliver vaginally. A major national goal is to reduce the risk of infection after surgery, and this finding is the culmination of investigative work over decades.”
A team of Michigan State University researchers has found that consuming an omega-3 fatty acid called DHA, or docosahexaenoic acid, can stop a known trigger of lupus and potentially other autoimmune disorders.
Researchers working with flies at IRB Barcelona describe that the concentration of some small intracellular organelles determines the branching capacity of tracheal cells. Tracheal cells are analogous to the cells that form blood vessels in the human body. The inhibition or stimulation of new blood vessels has implications in cancer and in tissue regeneration.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
